Korro Bio (KRRO) Stock Price, News & Analysis

Company Overview

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Key Stats

• Today's Range: $12.03 to $13.16
• 50-Day Range: $10.80 to $20.93
• 52-Week Range: $10.29 to $98.00
• Volume: 131,615 shs
• Average Volume: 110,736 shs
• Market Capitalization: $115.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $102.43
• Consensus Rating: Buy

Korro Bio Stock Analysis - MarketRank™

Korro Bio scored higher than 38% of companies evaluated by MarketBeat, and ranked 1489th out of 2,787 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Korro Bio has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Korro Bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Korro Bio are expected to decrease in the coming year, from ($9.52) to ($10.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Korro Bio is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Korro Bio is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Korro Bio has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

18.07% of the float of Korro Bio has been sold short.

Short Interest Ratio / Days to Cover

Korro Bio has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in Korro Bio has recently decreased by 7.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Korro Bio does not currently pay a dividend.

Dividend Growth

Korro Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

18.07% of the float of Korro Bio has been sold short.

Short Interest Ratio / Days to Cover

Korro Bio has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in Korro Bio has recently decreased by 7.29%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for KRRO on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Korro Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Korro Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.60% of the stock of Korro Bio is held by insiders.

Percentage Held by Institutions

Only 13.18% of the stock of Korro Bio is held by institutions.

KRRO Stock Analysis - Frequently Asked Questions

How have KRRO shares performed this year?

Korro Bio's stock was trading at $38.07 at the start of the year. Since then, KRRO shares have decreased by 67.6% and is now trading at $12.35.
View the best growth stocks for 2025 here.

How were Korro Bio's earnings last quarter?

Korro Bio, Inc. (NASDAQ:KRRO) announced its quarterly earnings data on Wednesday, May, 7th. The company reported ($2.49) EPS for the quarter, beating the consensus estimate of ($2.60) by $0.11. The company had revenue of $2.55 million for the quarter, compared to analysts' expectations of $0.13 million.

Who are Korro Bio's major shareholders?

Top institutional investors of Korro Bio include Driehaus Capital Management LLC (6.20%), Cormorant Asset Management LP (4.05%), Tri Locum Partners LP (1.37%) and Aberdeen Group plc (0.90%). Insiders that own company stock include Venture Opportunity Fund Atlas, David L Lucchino and Vineet Agarwal.
View institutional ownership trends.

How do I buy shares of Korro Bio?

Shares of KRRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Korro Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Korro Bio investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 6/20/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KRRO
• Previous Symbol: NASDAQ:KRRO
• CIK: 1703647
• Web: www.frequencytx.com
• Phone: 781-315-4600
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $102.43
• High Stock Price Target: $180.00
• Low Stock Price Target: $25.00
• Potential Upside/Downside: +716.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($9.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$83.58 million
• Net Margins: N/A
• Pretax Margin: -1,810.56%
• Return on Equity: -51.64%
• Return on Assets: -37.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.41
• Quick Ratio: 9.41

Sales & Book Value

• Annual Sales: $2.27 million
• Price / Sales: 51.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $17.12 per share
• Price / Book: 0.73

Miscellaneous

• Outstanding Shares: 9,390,000
• Free Float: 8,959,000
• Market Cap: $117.80 million
• Optionable: No Data
• Beta: 2.45